Literature DB >> 33621149

Current perspectives on galvanic vestibular stimulation in the treatment of Parkinson's disease.

Soojin Lee1,2, Aiping Liu3, Martin J McKeown1,4.   

Abstract

Introduction: Galvanic vestibular stimulation (GVS) is a noninvasive technique that activates vestibular afferents, influencing activity and oscillations in a broad network of brain regions. Several studies have suggested beneficial effects of GVS on motor symptoms in Parkinson's Disease (PD).Areas covered: A comprehensive overview of the stimulation techniques, potential mechanisms of action, challenges, and future research directions.Expert opinion: This emerging technology is not currently a viable therapy. However, a complementary therapy that is inexpensive, easily disseminated, customizable, and portable is sufficiently enticing that continued research and development is warranted. Future work utilizing biomedical engineering approaches, including concomitant functional neuroimaging, have the potential to significantly increase efficacy. GVS could be explored for other PD symptoms including orthostatic hypotension, dyskinesia, and sleep disorders.

Entities:  

Keywords:  Galvanic vestibular stimulation; eeg; fMRI; motor function; neuromodulation; parkinson’s disease; the vestibular system

Mesh:

Year:  2021        PMID: 33621149     DOI: 10.1080/14737175.2021.1894928

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  2 in total

Review 1.  Recent developments in the understanding of the interactions between the vestibular system, memory, the hippocampus, and the striatum.

Authors:  Paul F Smith
Journal:  Front Neurol       Date:  2022-09-02       Impact factor: 4.086

2.  Galvanic Vestibular Stimulation Improves Subnetwork Interactions in Parkinson's Disease.

Authors:  Aiping Liu; Huiling Bi; Yu Li; Soojin Lee; Jiayue Cai; Taomian Mi; Saurabh Garg; Jowon L Kim; Maria Zhu; Xun Chen; Z Jane Wang; Martin J McKeown
Journal:  J Healthc Eng       Date:  2021-05-13       Impact factor: 2.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.